Skip to main content

Table 1 per protocol analysis

From: Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab

 

ASAS20

ASAS40

Wk.

PLC

ADA

p

PLC

ADA

p

4

4 (31%)

9 (56%)

0.24

3 (23%)

7 (44%)

0.19

8

3 (23%)

10 (63%)

0.03*

3 (23%)

9 (56%)

0.07

12

4 (31%)

9 (63%)

0.17

4 (31)

9 (56%)

0.17

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096